Poly Medicure FY26 Revenue ₹1,875 Crore, Targets ₹2,400 Crore in FY27

FY26 Consolidated Revenue: ₹1,875 crore
Q4 FY26 Consolidated Revenue: ₹534 crore

Reader Takeaway: Strategic shift to high-tech devices and growth targets are positives; import competition and margin pressures are key watch points.

What just happened

Poly Medicure Ltd announced its financial results for the fiscal year ending March 2026 (FY26) and the fourth quarter (Q4 FY26). The company reported consolidated revenue of ₹1,875 crore for FY26, marking a 12.3% growth over the previous year. In Q4 FY26, consolidated revenue stood at ₹534 crore, showing a significant 21% year-on-year increase. The company also provided guidance for FY27, projecting consolidated revenue between ₹2,300 crore and ₹2,400 crore.

Why this matters

This performance and forward-looking guidance indicate Poly Medicure's strategic direction and growth ambitions. The company is actively transitioning towards higher-margin, high-growth segments such as orthopedics, cardiology, neonatology, oncology, and renal care. This strategic shift aims to improve profitability and market positioning. The FY27 revenue target suggests management's confidence in sustaining growth momentum despite potential market challenges.

The backstory

Poly Medicure has been focused on expanding its product portfolio and market reach. In FY26, consolidated capital expenditure (capex) was ₹296 crore. The company is integrating recent acquisitions, including PendraCare and Citieffe, and completed a small acquisition in Brazil for approximately USD 40,000. This strategic acquisition in Brazil was intended to bypass regulatory timelines for import licenses, highlighting the company's proactive approach to market access.

What changes now

The company's revenue mix is evolving, with a decrease in the share of Infusion Therapy from 57% to 50% and a corresponding increase in higher-complexity products. The renal segment has seen significant capacity expansion, with installed capacity reaching around 1,000 machines and 450 machines placed in FY26. The capex for FY27 is planned between ₹200–₹225 crore.

Risks to watch

Management has identified competitive pressures from Chinese imports, where finished goods face lower duties than raw materials, leading to cost inversion. Supply chain disruptions, particularly on key shipping routes, are also impacting export fulfillment. Additionally, gross margins saw a slight sequential dip in Q4 due to product mix changes, and management noted potential erosion if crude-linked costs remain high.

Peer comparison

While specific peer data is not provided in the filing, Poly Medicure's strategic pivot mirrors a broader trend in the medical devices sector towards specialization and higher-value products. The company's focus on segments like cardiology and renal care places it in competitive areas where technological innovation and regulatory navigation are key.

Context metrics (time-bound)

• FY26 Consolidated Revenue: ₹1,875 crore (12.3% growth)
• Q4 FY26 Consolidated Revenue: ₹534 crore (21% YoY growth)
• FY26 Consolidated Capex: ₹296 crore
• FY27 Consolidated Revenue Guidance: ₹2,300–₹2,400 crore
• FY27 Capex Guidance: ₹200–₹225 crore

What to track next

Investors should closely monitor the successful integration of recent acquisitions and their contribution to revenue and margins. Management's strategies to mitigate the impact of Chinese imports and address cost inversion will be crucial. Furthermore, tracking gross margin trends and the growth trajectory in specialized segments like renal care will be important indicators of the company's strategic execution.